| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2116711 | Cancer Letters | 2008 | 7 Pages |
Abstract
Recent pharmacogenetic studies on irinotecan have revealed the impact of UDP glucuronosyltransferase (UGT) 1A1â28 on severe irinotecan toxicities. Although the clinical role of UGT1A1â6, which is specifically detected in East Asian patients, in irinotecan toxicities is suggested, clear evidence remains limited. To examine the impact of â6, the association of UGT1A1 genotypes with severe irinotecan toxicities was retrospectively investigated in Japanese cancer patients. A significant â6-dependent increase in the incidence of grade 3 or 4 neutropenia was observed in 49 patients on irinotecan monotherapy (p = 0.012). This study further clarifies the clinical importance of â6 in irinotecan therapy in East Asians.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Kimie Sai, Yoshiro Saito, Hiromi Sakamoto, Kuniaki Shirao, Koichi Kurose, Mayumi Saeki, Shogo Ozawa, Nahoko Kaniwa, Setsuo Hirohashi, Nagahiro Saijo, Jun-ichi Sawada, Teruhiko Yoshida,